|
|
|
| Therapeutic effect comparison of Flupentixol Melitracen and Bailemian in the treatment of moderate and severe chronic obstructive pulmonary disease with anxiety or depression |
| LE Liang FENG Xuan NI Hong-yan |
| Department of Pharmacy,Jingdezhen First People′s Hospital |
|
|
|
|
Abstract Objective To compare the effect of Flupentixol Melitracen and Bailemian in the treatment of moderate and severe chronic obstructive pulmonary disease complicated with anxiety or depression.Methods From January 2017 to December 2019,150 patients with moderate and severe chronic obstructive pulmonary disease complicated with anxiety or depression treated in the Jingdezhen First People′s Hospital were selected as subjects.They were divided into three groups with 50 cases in each group by random number table method.The control group was given conventional symptomatic treatment,the observation group 1 was given conventional symptomatic treatment + oral Flupentixol Melitracen treatment,and the observation group 2 was given conventional symptomatic treatment + Bailemian treatment.The degree of anxiety and depression,quality of life,treatment effect and adverse reactions were compared among the three groups before and after 4 weeks of treatment.Results Comparison ofthe scores of hospital anxiety and depression scale(HADS),chronic obstructive pulmonary disease assessment test (CAT) and BODE index (B for body mass index,O for airflow obstruction,D for dyspnea,E for exercise ability) before treatment among the three groups showed no statistically significant differences (P＞0.05).After 4 weeks of treatment,the anxiety subscale score in the observation group 2 was(8.11±1.03) points,depression subscale score in the observation group 2 was (8.17±1.87) points,CAT score in the observation group 2 was (24.03±2.16) points,BODE index in observation group 2 was (4.25±0.62) points,were lower than those in the observation group 1 of (11.58±2.42),(10.49±2.38) (27.17±2.54),(5.98±0.79) points,and lower than those of the control group of (12.25±3.11),(12.12±3.09),(28.36±2.63),(6.48±0.85) points,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions among the three groups (P＞0.05).Conclusion Bailemian treatment can improve the negative emotions of patients with moderate and severe chronic obstructive pulmonary disease complicated with anxiety or depression,improve the quality of life of patients,and has fewer adverse reactions,so it can be used as the first choice for clinical treatment.
|
|
|
|
|
|
| [1] |
黄效梅，周丹.肺康复训练对缓解高龄慢性阻塞性肺疾病患者焦虑及抑郁的效果分析[J].检验医学与临床，2018，15（8）：148-151.
|
| [2] |
陈晓燕，李啸.氟哌噻吨美利曲辛联合心理干预在慢性阻塞性肺疾病伴焦虑抑郁患者中的应用效果[J].中国医药导报，2017，14（13）：65-68.
|
| [3] |
郭静，杨金锁，陈静非，等.经颅磁刺激联合百乐眠胶囊治疗肝气郁结型抑郁失眠的效果[J].医学临床研究，2019，36（10）：1965-1967.
|
| [4] |
中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.慢性阻塞性肺疾病基层诊疗指南（实践版·2018）[J].中华全科医师杂志，2018，17（11）：871.
|
| [5] |
中华医学会精神科分会.CCMD-3 中国精神障碍分类与诊断标准[M].济南：山东科学技术出版社，2001：105-107.
|
| [6] |
李田园，潘琦，张梅，等.应用医院用焦虑抑郁量表探讨住院2型糖尿病患者焦虑抑郁的发生风险[J].中国糖尿病杂志，2019，27（9）：671-676.
|
| [7] |
刘冬，林智峰，许西琳，等.不同时期慢性阻塞性肺疾病患者评估测试量表评分、肺功能与呼出气冷凝液中白细胞介素17、白细胞介素8 的相关性[J].临床误诊误治，2018，31（5）：82-86.
|
| [8] |
赵丽丽，雍佳辉，李涛，等.跨理论模型干预对老年慢性阻塞性肺疾病患者BODE 指数的影响研究[J].重庆医学，2018，47（27）：3596-3599.
|
| [9] |
付茜.百乐眠胶囊联合曲唑酮治疗中度抑郁症的临床研究[J].现代药物与临床，2019，34（10）：2957-2960.
|
| [10] |
周爱华.综合护理干预对老年慢性阻塞性肺疾病稳定期病人肺功能、心理状态及睡眠质量的影响[J].护理研究，2018，32（21）：153-156.
|
| [11] |
龚放华，杨燕妮，张婷.心肺康复训练对稳定期老年COPD患者心肺功能、生活质量及心理状况的影响[J].医学临床研究，2017，34（9）：1746-1748.
|
| [12] |
周爱华.综合护理干预对老年慢性阻塞性肺疾病稳定期病人肺功能、心理状态及睡眠质量的影响[J].护理研究，2018，32（21）：153-156.
|
| [13] |
郭欣，李玉超，刘震宇.氟哌噻吨美利曲辛片对慢性阻塞性肺疾病合并焦虑抑郁症状患者的临床影响[J].中华老年多器官疾病杂志，2019，18（7）：523-526.
|
| [14] |
张东子，陈亚兰，刘建丛.百乐眠胶囊联合艾司西酞普兰片治疗失眠伴抑郁焦虑的临床效果[J].中国医药导报，2019，16（17）：133-136.
|
| [15] |
李亚平，郭子仪.百乐眠胶囊治疗老年神经衰弱后患者血清中BDNF、5-HT 水平变化意义[J].解放军预防医学杂志，2018，36（11）：69-72.
|
|
|
|
